Eugene, Oregon and Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - Silo Wellness Inc. (CSE: SILO) ("Silo," or the "Company")…
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED)…
NCCN Guidelines® recommend FES PET for systemic staging in certain patients with invasive lobular cancer (ILC), which could facilitate greater…
May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage…
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two…
BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform…
NEW YORK, May 30, 2025 /PRNewswire/ -- UP Fintech Holding Limited (NASDAQ: TIGR) ("UP Fintech" or the "Company"), announced its unaudited…
Two pioneering scientists received The Brain Prize 2025 for their discoveries that open an entirely new way of thinking about…
Data presented by Delix Therapeutics at the 2025 American Society of Clinical Psychopharmacology (ASCP) Conference confirms the NeuLogiq® Platform is…
New evidence from the largest prospective evaluation of stroke AI imaging further validates Brainomix 360 Stroke impact on mechanical thrombectomy,…